AXGN logo

AXGN

Axogen Inc.

$44.84
+$0.27(+0.61%)
61
Overall
40
Value
72
Tech
73
Quality
How is this score calculated?
Market Cap
$2.31B
Volume
1.30M
52W Range
$9.35 - $45.83
Target Price
$50.22

Company Overview

Mkt Cap$2.31BPrice$44.84
Volume1.30MChange+0.61%
P/E Ratio-147.0Open$45.50
Revenue$225.2MPrev Close$44.57
Net Income$-15.7M52W Range$9.35 - $45.83
Div YieldN/ATarget$50.22
Overall61Value40
Quality73Technical72

No chart data available

About Axogen Inc.

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Sector: Healthcare
Industry: Medical Devices

Latest News

AxoGen’s New Head-to-Head Nerve Repair Study Puts Avance Graft Under the Spotlight

AxoGen ($AXGN) announced an update on their ongoing clinical study. The study “A Prospective, Randomized, Assessor-Blinded, Multicenter Study Compa...

TipRanks Clinical-Trials-Auto-Generated Newsdesk3 days ago
ABCD
1SymbolPriceChangeVol
2AXGN$44.84+0.6%1.30M
3
4
5
6

Get Axogen Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.